RxDoctor Payments Data

Warren Conway, MD

Family Medicine · San Angelo, TXNPI 1245290717

Payments from drug & device makers

$1,813,226in general payments, 2019–2025

Across 697 payments — averaging $2601.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1.2M
  • Bavarian Nordic A/s$553K
  • Sekisui Diagnostics LLC$15K
  • Eli Lilly$10K
  • Novo Nordisk$2K
  • AbbVie$2K
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$3,15326%
  • Food & beverage$9,18074%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,813,226 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$173,775
Medicare patients
468
Services billed
3,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$171,463
JardianceEmpagliflozin170$141,829
EliquisApixaban78$65,640
TrulicityDulaglutide37$57,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$51,568
MounjaroTirzepatide39$41,350
RybelsusSemaglutide21$22,564
InvokanaCanagliflozin26$22,368
ProliaDenosumab13$21,525
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$19,905
CreonLipase/Protease/Amylase16$15,998
Tresiba Flextouch U-200Insulin Degludec30$15,940
XareltoRivaroxaban15$13,587
LinzessLinaclotide15$13,335
Breo ElliptaFluticasone/Vilanterol19$10,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,008$194,027177 claims
Boehringer IngelheimJardiance$399$141,829170 claims
Lilly USA, LLCTrulicity, Mounjaro$447$98,57376 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$185$67,02388 claims
PfizerEliquis$316$65,64078 claims
Johnson & JohnsonInvokana, Xarelto$126$35,95641 claims
AbbVieCreon, Linzess, Synthroid$1,621$32,53484 claims
AmgenProlia$302$21,52513 claims
MerckJanuvia$229$8,06812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →